
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is expected to continue its positive growth trajectory with the launch and approval of its Mobi Tubeless patch pump in 2026, along with a strong focus on the pharmacy channel. The company's projected weighted average gross margin and year-over-year revenue growth indicate potential for improved profitability and increased market share. While there may be some revenue challenges in the near future, successful execution of their plans could result in faster profit growth. Risks to the upside include gaining more market share and successfully entering the pharmacy channel.
Bears say
Tandem Diabetes Care is facing pressure from competitors in the market for insulin pumps and infusion sets, as well as potential execution risks related to converting patients to the pharmacy channel. Although the company's recent launch of its smaller Mobi pump and continued development of Tobi and Sigi could drive sales, the majority of Tandem's revenue comes from the US, limiting its potential for global growth. The company has also struggled in recent quarters with meeting revenue guidance and there are potential risks related to product development timelines and new product introductions. Additionally, the current valuation for Tandem is relatively low compared to its peers, but a successful transition to a pay-as-you-go model could drive higher recurring revenues and profit in the future.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares